An innovative clinical study has found that providing pluripotent cells to unborn babies affected by spina bifida as part of a surgical repair can be a "major milestone" in treating birth defects.
Study Parameters and Security
The US-based trial examined six unborn babies with the 'open' form of spina bifida. Surgeons applied placenta-derived mesenchymal stem cells directly onto the infant's spine as part of the surgical correction.
Critically, the cell therapy was found to be safe. Doctors verified that the therapy did not induce neoplasms, disrupt the healing process, or impede the resolution of co-occurring hindbrain herniation.
Positive Developments
Imaging conducted after delivery indicated a complete reversal of Chiari malformation in all six infants. This brain structure normalization is a key indicator for better mobility and function.
"In the event it allows more children capable of walking who wouldn't have, it may emerge as their standard of care," commented the principal investigator. "The outcomes appear profoundly encouraging and open the door to a variety of prospective novel therapies."
Long-Term Prospects and Optimism
Experts not involved in the trial proposed that additional validation of these apparent benefits could herald a "different age" in fetal surgery. The potential to improve neural deficits occurring during fetal development is viewed as a paradigm-shifting aim.
Especially significant would be improvements in bladder and bowel function, which are common challenges for individuals living with this disorder.
The Path Forward
Although this preliminary study focused on a handful of cases, its established security and encouraging indicators create a solid basis for expanded clinical research. The addition of cellular treatment with current in-utero repair procedures holds considerable promise for transforming outcomes for infants diagnosed prenatally with myelomeningocele.